MA54327B1 - Inhibiteurs de kras g12c - Google Patents
Inhibiteurs de kras g12cInfo
- Publication number
- MA54327B1 MA54327B1 MA54327A MA54327A MA54327B1 MA 54327 B1 MA54327 B1 MA 54327B1 MA 54327 A MA54327 A MA 54327A MA 54327 A MA54327 A MA 54327A MA 54327 B1 MA54327 B1 MA 54327B1
- Authority
- MA
- Morocco
- Prior art keywords
- kras
- inhibitors
- compounds
- salts
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des composés de formule : où r1, r2, r3, r4, r5, a, b et y sont tels que décrits dans la description, des sels pharmaceutiquement acceptables de ceux-ci, ainsi que des procédés d'utilisation de ces composés et de ces sels pour traiter des patients atteints d'un cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946586P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/063272 WO2021118877A1 (fr) | 2019-12-11 | 2020-12-04 | Inhibiteurs de kras g12c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54327A MA54327A (fr) | 2022-04-13 |
| MA54327B1 true MA54327B1 (fr) | 2022-12-30 |
Family
ID=74106135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54327A MA54327B1 (fr) | 2019-12-11 | 2020-12-04 | Inhibiteurs de kras g12c |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11731984B2 (fr) |
| EP (1) | EP3886991B1 (fr) |
| JP (1) | JP7023421B2 (fr) |
| KR (1) | KR102546592B1 (fr) |
| CN (2) | CN117820333A (fr) |
| AR (1) | AR120700A1 (fr) |
| AU (3) | AU2020402701B2 (fr) |
| CA (1) | CA3161162A1 (fr) |
| CL (1) | CL2022001513A1 (fr) |
| CO (1) | CO2022008091A2 (fr) |
| CR (1) | CR20220258A (fr) |
| DK (1) | DK3886991T3 (fr) |
| DO (1) | DOP2022000117A (fr) |
| EC (1) | ECSP22046699A (fr) |
| ES (1) | ES2929700T3 (fr) |
| HR (1) | HRP20221301T1 (fr) |
| HU (1) | HUE060684T2 (fr) |
| IL (3) | IL293394B2 (fr) |
| JO (2) | JOP20220142B1 (fr) |
| LT (1) | LT3886991T (fr) |
| MA (1) | MA54327B1 (fr) |
| MD (1) | MD3886991T2 (fr) |
| MX (2) | MX2022006986A (fr) |
| PE (1) | PE20230238A1 (fr) |
| PH (1) | PH12022551424A1 (fr) |
| PL (1) | PL3886991T3 (fr) |
| PT (1) | PT3886991T (fr) |
| RS (1) | RS63719B1 (fr) |
| SA (1) | SA522432955B1 (fr) |
| SI (1) | SI3886991T1 (fr) |
| TW (1) | TWI765448B (fr) |
| UA (1) | UA128806C2 (fr) |
| WO (1) | WO2021118877A1 (fr) |
| ZA (1) | ZA202205218B (fr) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI831855B (zh) | 2018-10-26 | 2024-02-11 | 日商大鵬藥品工業股份有限公司 | 新穎吲唑化合物或其鹽 |
| CA3158793A1 (fr) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Inhibiteurs a petites molecules de mutant de kras g12c |
| WO2021106230A1 (fr) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | Nouveau composé phénolique ou sel de celui-ci |
| WO2023205701A1 (fr) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques et leurs utilisations |
| TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| AU2021285032A1 (en) | 2020-06-02 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4203952A4 (fr) | 2020-08-28 | 2024-12-11 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| CA3187757A1 (fr) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Utilisation d'inhibiteurs de sos1 pour traiter des malignites a mutations de shp2 |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| CN114437107B (zh) * | 2020-11-06 | 2025-04-04 | 江苏先声药业有限公司 | 哌嗪类化合物及其应用 |
| TWI880049B (zh) * | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c抑制劑 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022266206A1 (fr) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Conjugués d'inhibiteurs de kras |
| MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| WO2023066371A1 (fr) | 2021-10-22 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | Composé tétracyclique contenant de l'azote, son procédé de préparation et son utilisation médicale |
| CN119013272A (zh) * | 2021-12-01 | 2024-11-22 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 |
| TW202340209A (zh) * | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| EP4441051A1 (fr) * | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Composés de dégradation de kras comprenant des 2-amino-3-cyano thiophènes annelés |
| WO2023099623A1 (fr) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | 2-amino-3-cyano-thiophènes annelés et dérivés pour le traitement du cancer |
| CR20240233A (es) * | 2021-12-01 | 2024-07-17 | Univ Vanderbilt | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer |
| AU2022421224A1 (en) | 2021-12-22 | 2024-06-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| JP2025503511A (ja) | 2021-12-28 | 2025-02-04 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲート及びｒａｓｇ１２ｃ阻害剤の組み合わせ |
| WO2023168036A1 (fr) * | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Procédé de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs de shp2 |
| EP4489738A4 (fr) | 2022-03-11 | 2026-03-18 | Kumquat Biosciences Inc | Composés hétérocycliques et leurs utilisations |
| MX2024011631A (es) | 2022-03-25 | 2024-09-30 | Lilly Co Eli | Inhibidores de kras. |
| EP4504710A1 (fr) | 2022-04-07 | 2025-02-12 | Eli Lilly and Company | Procédé de fabrication d'un inhibiteur de kras g12c |
| EP4504209A1 (fr) | 2022-04-08 | 2025-02-12 | Eli Lilly and Company | Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a |
| CN117642408A (zh) * | 2022-06-24 | 2024-03-01 | 暨南大学 | 含硒杂环类化合物及其药用组合物和应用 |
| EP4547251A1 (fr) | 2022-06-30 | 2025-05-07 | Eli Lilly and Company | Inhibiteur de kras g12c pour le traitement du cancer |
| TW202409051A (zh) | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| KR20250060956A (ko) | 2022-08-05 | 2025-05-07 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| JP2025528836A (ja) | 2022-08-17 | 2025-09-02 | ツリーライン バイオサイエンシズ インコーポレイテッド | ピリドピリミジンＫＲａｓ阻害剤 |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| AU2023349002A1 (en) | 2022-09-30 | 2025-05-15 | Trasveda Ltd. | Compounds with anti-kras mutant tumor activity |
| WO2024081674A1 (fr) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Polythérapies pour le traitement du cancer |
| JP2025541682A (ja) | 2022-11-21 | 2025-12-23 | ツリーライン バイオサイエンシズ インコーポレイテッド | スピロ環式ジヒドロピランピリミジンＫＲａｓ阻害剤 |
| EP4688784A1 (fr) | 2023-03-30 | 2026-02-11 | Eli Lilly and Company | Inhibiteurs de kras |
| AU2024241889A1 (en) | 2023-03-31 | 2025-09-25 | Eli Lilly And Company | Kras inhibitors |
| KR20250174948A (ko) | 2023-04-21 | 2025-12-15 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 테트라시클릭 화합물의 결정 형태 및 이의 제조 방법 |
| EP4720059A1 (fr) | 2023-05-24 | 2026-04-08 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| CN121219016A (zh) | 2023-06-02 | 2025-12-26 | 第一三共株式会社 | 抗-her3抗体-药物缀合物和rasg12c抑制剂的组合 |
| AU2024285370A1 (en) | 2023-06-06 | 2026-01-08 | Kumquat Biosciences Inc. | Substituted heterocycles and uses thereof |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024344161A1 (en) | 2023-09-21 | 2026-03-26 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| CN121909201A (zh) | 2023-09-27 | 2026-04-21 | 伊莱利利公司 | Kras抑制剂 |
| IL327380A (en) | 2023-09-29 | 2026-05-01 | D3 Bio Wuxi Co Ltd | Combinations of WX-001 or its derivatives with KRAS G12C inhibitor for use in cancer treatment |
| AU2024358622A1 (en) | 2023-10-11 | 2026-04-16 | Eli Lilly And Company | Process for making a kras g12c inhibitor |
| WO2025085748A1 (fr) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Inhibiteurs à petites molécules de protéines kras |
| WO2025245127A1 (fr) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Inhibiteurs de dihydropyranopyrimidine kras spirocycliques |
| WO2026035945A1 (fr) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Conjugués médicamenteux induits par covalence ciblant kras et comprenant une charge utile de topoisomérase |
| WO2026035947A1 (fr) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Conjugués médicamenteux à induction par liaison covalente ciblant kras comprenant une charge utile de topo-isomérase |
| WO2026059955A1 (fr) | 2024-09-11 | 2026-03-19 | Eli Lilly And Company | Dérivés de (3-((6-(2-amino-benzo[d]thiazol-4-yl)-3-(pyrrolidin-1-yl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)amino)-pipéridin-2-one utilisés en tant qu'inhibiteurs de kras pour le traitement du cancer |
| WO2026064527A1 (fr) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Conjugués médicamenteux à induction covalente ciblant kras comprenant une charge utile d'inhibiteur de tubuline |
| WO2026064520A1 (fr) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Conjugués médicamenteux à induction covalente ciblant kras et comprenant une charge utile inhibitrice de tubuline |
| WO2026075942A1 (fr) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Inhibiteurs de kras |
| US12600733B2 (en) | 2024-10-01 | 2026-04-14 | Eli Lilly And Company | KRAS inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007661A1 (fr) * | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique tricycique et son utilisation |
| JO3805B1 (ar) * | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JP6559123B2 (ja) | 2013-10-10 | 2019-08-14 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの阻害剤 |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| AR111776A1 (es) | 2017-05-11 | 2019-08-21 | Astrazeneca Ab | Heteroarilos inhibidores de las proteínas ras mutantes de g12c |
| JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ，インコーポレイテッド | がんを治療するためのｓｈｐ２阻害剤組成物および方法 |
| CN111051306B (zh) * | 2017-09-08 | 2023-01-03 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
| KR102861303B1 (ko) * | 2017-11-15 | 2025-09-17 | 미라티 테라퓨틱스, 인크. | Ｋｒａｓ ｇ12ｃ 억제제 |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| AR116604A1 (es) | 2018-10-15 | 2021-05-26 | Lilly Co Eli | Inhibidores de kras g12c |
| PH12021552083A1 (en) * | 2019-03-05 | 2022-06-06 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| CN112390818B (zh) | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途 |
-
2020
- 2020-12-04 RS RS20220956A patent/RS63719B1/sr unknown
- 2020-12-04 MD MDE20210978T patent/MD3886991T2/ro unknown
- 2020-12-04 CN CN202311816497.XA patent/CN117820333A/zh active Pending
- 2020-12-04 IL IL293394A patent/IL293394B2/en unknown
- 2020-12-04 IL IL326964A patent/IL326964A/en unknown
- 2020-12-04 SI SI202030102T patent/SI3886991T1/sl unknown
- 2020-12-04 ES ES20834024T patent/ES2929700T3/es active Active
- 2020-12-04 PL PL20834024.0T patent/PL3886991T3/pl unknown
- 2020-12-04 WO PCT/US2020/063272 patent/WO2021118877A1/fr not_active Ceased
- 2020-12-04 CA CA3161162A patent/CA3161162A1/fr active Pending
- 2020-12-04 PT PT208340240T patent/PT3886991T/pt unknown
- 2020-12-04 UA UAA202201784A patent/UA128806C2/uk unknown
- 2020-12-04 CN CN202080085553.5A patent/CN114828964B/zh active Active
- 2020-12-04 PH PH1/2022/551424A patent/PH12022551424A1/en unknown
- 2020-12-04 DK DK20834024.0T patent/DK3886991T3/da active
- 2020-12-04 TW TW109142894A patent/TWI765448B/zh active
- 2020-12-04 CR CR20220258A patent/CR20220258A/es unknown
- 2020-12-04 HU HUE20834024A patent/HUE060684T2/hu unknown
- 2020-12-04 AU AU2020402701A patent/AU2020402701B2/en active Active
- 2020-12-04 MA MA54327A patent/MA54327B1/fr unknown
- 2020-12-04 HR HRP20221301TT patent/HRP20221301T1/hr unknown
- 2020-12-04 PE PE2022001047A patent/PE20230238A1/es unknown
- 2020-12-04 MX MX2022006986A patent/MX2022006986A/es unknown
- 2020-12-04 EP EP20834024.0A patent/EP3886991B1/fr active Active
- 2020-12-04 US US17/111,676 patent/US11731984B2/en active Active
- 2020-12-04 KR KR1020227019240A patent/KR102546592B1/ko active Active
- 2020-12-04 LT LTEPPCT/US2020/063272T patent/LT3886991T/lt unknown
- 2020-12-04 JP JP2021539866A patent/JP7023421B2/ja active Active
- 2020-12-04 IL IL304534A patent/IL304534B1/en unknown
- 2020-12-09 AR ARP200103420A patent/AR120700A1/es unknown
-
2022
- 2022-05-11 ZA ZA2022/05218A patent/ZA202205218B/en unknown
- 2022-06-07 CO CONC2022/0008091A patent/CO2022008091A2/es unknown
- 2022-06-07 DO DO2022000117A patent/DOP2022000117A/es unknown
- 2022-06-08 CL CL2022001513A patent/CL2022001513A1/es unknown
- 2022-06-08 MX MX2025002170A patent/MX2025002170A/es unknown
- 2022-06-09 JO JOJO/P/2022/0142A patent/JOP20220142B1/ar active
- 2022-06-10 EC ECSENADI202246699A patent/ECSP22046699A/es unknown
- 2022-06-12 SA SA522432955A patent/SA522432955B1/ar unknown
-
2023
- 2023-06-28 US US18/343,326 patent/US20230339968A1/en active Pending
-
2024
- 2024-04-18 AU AU2024202573A patent/AU2024202573B2/en active Active
- 2024-09-30 JO JOJO/P/2024/0216A patent/JOP20240216A1/ar unknown
-
2026
- 2026-04-13 AU AU2026202752A patent/AU2026202752A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| MA45920B1 (fr) | Inhibiteurs de pyridopyrimidinone cdk2/4/6 | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MX2022001671A (es) | Sales de un inhibidor de pd-1/pd-l1. | |
| MA52360B1 (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA30652B1 (fr) | Composes organiques | |
| MA65131A1 (fr) | Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t | |
| MA34207B1 (fr) | Inhibiteurs de la pi3 kinase et/ou du mtor | |
| TN2014000115A1 (fr) | Derives de pyrrolopyrimidines et de purines | |
| MA37383A1 (fr) | Compose heterobicycliques comme inhibiteurs de la beta lactamase | |
| MA33240B1 (fr) | Inhibiteurs de bêta-sécrétase | |
| MA37891B1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
| MA31419B1 (fr) | Derives de pyridine | |
| MA31873B1 (fr) | Inhibiteurs de la peptide déformylase | |
| MA30166B1 (fr) | Imidazoles substitues et leur utilisation comme pesticides. | |
| MA35184B1 (fr) | Antagonistes de trpv4 | |
| MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA39043B1 (fr) | Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs | |
| SE0301232D0 (sv) | Novel use |